Leqvio (Inclisiran) Cost in Kentucky 2026: Coverage, Compounding, and How to Pay Less

What Is Inclisiran and Why Does the Price Matter in Kentucky?

Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, cutting LDL-C production at its source rather than blocking the PCSK9 protein after it is already made. The FDA approved it on December 22, 2021, under the brand name Leqvio for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of maximally tolerated statin therapy [1].

Kentucky carries one of the highest rates of cardiovascular disease mortality in the United States. The CDC reports that Kentucky's age-adjusted heart disease death rate sits at 231.4 per 100,000 population, well above the national average of 179.5 [2]. That context makes LDL-lowering access a genuine public-health question, not just a pharmacy-benefit footnote.

The drug's twice-yearly injection schedule is one of its biggest practical advantages. A physician or nurse administers 284 mg subcutaneously on Day 1, again at Day 90, and then every 6 months thereafter. Patients do not self-inject. Because there are only two maintenance injections per year, the total administered doses are low even if the per-unit list price is high [3].

How Much Does Leqvio Cost in Kentucky in 2026?

The Novartis wholesale acquisition cost (WAC) translates to approximately $3,240 per injection, or roughly $540 per month when annualized across the two-dose maintenance schedule. Cash-pay prices at Kentucky retail pharmacies mirror that WAC closely, averaging around $540 per month equivalent in 2026 [4].

That number sounds steep, and for uninsured Kentuckians it is. But the real out-of-pocket cost depends heavily on insurance status and program eligibility, as the sections below explain. Comparable PCSK9 inhibitors alirocumab (Praluent) and evolocumab (Repatha) carry similar list prices, though all three have seen payer negotiations reduce net costs over time [5].

The American College of Cardiology's 2022 Expert Consensus Decision Pathway on Non-Statin Therapies states: "Inclisiran may be considered for patients with ASCVD or HeFH who require additional LDL-C lowering and who cannot tolerate or do not respond adequately to PCSK9 inhibitor antibodies" [6]. That framing matters for prior authorization, because it positions inclisiran as a later-line option in most insurer step-therapy protocols, which affects how quickly Kentucky patients can access it.

Does Kentucky Medicaid Cover Leqvio?

Kentucky Medicaid does not cover Leqvio as of 2026. The Kentucky Department for Medicaid Services (KDMS) Preferred Drug List does not include inclisiran among covered lipid-lowering agents for the standard Medicaid fee-for-service population [7]. Managed care organizations (MCOs) that administer Kentucky Medicaid, including Anthem, Humana CareSource, Molina, and WellCare, follow KDMS guidance and have not independently added inclisiran to their formularies at the time of this writing.

This is not unusual nationally. Medicaid programs in most states have been slow to add high-cost PCSK9 agents, often citing cost-effectiveness thresholds. A 2022 JAMA Internal Medicine analysis found that at list price, PCSK9 inhibitors exceed $100,000 per quality-adjusted life-year in many Medicaid populations, well above conventional cost-effectiveness benchmarks [8].

Kentucky Medicaid patients who need aggressive LDL reduction should discuss alternative options with their provider, including high-intensity statins (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg per ACC/AHA guidelines), ezetimibe, and bempedoic acid, all of which appear on the Kentucky Medicaid PDL [9].

If a provider believes a specific patient has an exceptional clinical need, a prior authorization exception request submitted with ORION trial data and documentation of statin intolerance may occasionally succeed, though approval rates remain low.

Which Private Insurance Plans Cover Leqvio in Kentucky?

Coverage varies by plan tier and employer. Here is what Kentucky patients typically encounter:

Commercial employer-sponsored plans. Large-group plans administered by Anthem Blue Cross Blue Shield of Kentucky, Humana, Aetna, and UnitedHealthcare generally place inclisiran on a specialty tier requiring prior authorization. Step therapy requiring documented failure of at least one maximally tolerated statin plus ezetimibe is standard. Some plans also require a documented LDL above 70 mg/dL despite optimized oral therapy [10].

ACA Marketplace plans in Kentucky. Kentucky operates its exchange through kynect. Marketplace silver and gold plans sold by Anthem and Humana typically carry Leqvio on Tier 4 or Tier 5 specialty formulary. After deductible, coinsurance of 20 to 30% on a $3,240 claim translates to $648, $972 per injection before any savings card offset.

Medicare Part D. Inclisiran is covered under most Part D plans, but placement and cost-sharing vary widely. The Inflation Reduction Act's $2,000 out-of-pocket cap, now fully in effect for 2025 and 2026, provides meaningful protection for Medicare beneficiaries who reach catastrophic coverage. CMS data show that Part D enrollees' average out-of-pocket spending on specialty lipid agents dropped approximately 34% in 2025 following the IRA cap implementation [11].

Medicare Part B. Because a physician or qualified clinical staff member must administer Leqvio, it may qualify for reimbursement under Part B as a physician-administered drug rather than Part D. CMS has a reimbursement pathway under HCPCS code J3490/J3590 for unlisted drugs and a specific J-code process. Patients should confirm billing with their cardiologist or lipid clinic [12].

How Does the Novartis Leqvio Savings Card Work in Kentucky?

The Novartis Patient Assistance Foundation and the Leqvio commercial copay program are the two main manufacturer-sponsored cost reduction tools available to Kentucky patients.

Commercial copay card. Commercially insured patients who are not enrolled in any federal or state government health program (including Medicare, Medicaid, TRICARE, or VA) may qualify for the Novartis Leqvio copay card, which can reduce the patient's copay to as low as $0 per injection for eligible plans. The annual benefit cap and specific eligibility criteria are set by Novartis and subject to change; patients should verify current terms at novartis.com or through their prescribing provider [13].

Novartis Patient Assistance Program (PAP). Uninsured or underinsured Kentuckians whose household income is at or below 400% of the federal poverty level may qualify for free medication through the Novartis PAP. Applications require income documentation and a prescriber statement [14].

Important limitation. Neither the copay card nor the PAP is available to Medicare or Medicaid enrollees under federal anti-kickback guidelines. This creates a significant access gap for Kentucky's large dual-eligible population.

Is Compounded Inclisiran Legal in Kentucky?

Compounded inclisiran is legal in Kentucky when prepared by a state-licensed 503A compounding pharmacy operating under Kentucky Board of Pharmacy regulations [15]. A 503A pharmacy compounds medications for an individual patient based on a valid patient-specific prescription from a licensed prescriber.

This is a nuanced legal area. The FDA does not approve compounded drugs, and compounded inclisiran is not bioequivalent-tested against Novartis's Leqvio. The active pharmaceutical ingredient (API) used by compounders must meet USP standards, and sterility testing is required for injectable preparations [16].

The FDA has not placed inclisiran on its list of drugs that may not be compounded (the "Difficult to Compound" list), and inclisiran's API is commercially available to licensed compounding pharmacies [17]. That means 503A pharmacies in Kentucky can legally compound it for individual patients.

Cash prices for compounded inclisiran vary by pharmacy. Some 503A pharmacies list compounded inclisiran at prices substantially below the Novartis WAC, though specific pricing should be obtained directly from the dispensing pharmacy. Patients and providers should verify the pharmacy's accreditation (PCAB accreditation from the Pharmacy Compounding Accreditation Board is one quality marker) and confirm sterility and potency testing protocols before dispensing [18].

Clinically, providers prescribing compounded inclisiran should document informed consent that the patient understands they are receiving a non-FDA-approved formulation, and should track LDL-C response the same way they would with brand Leqvio. The ORION trials used the Novartis formulation specifically; any efficacy inference for compounded product is extrapolated, not directly proven.

What Does the Clinical Evidence Say About Inclisiran's Effectiveness?

The ORION-10 and ORION-11 trials, published in the New England Journal of Medicine in 2020, provide the key efficacy data. ORION-10 (N=1,561, patients with ASCVD) showed inclisiran 284 mg reduced LDL-C by 52.3% from baseline versus a 1.5% increase in the placebo group at Day 510 (P<0.001) [19]. ORION-11 (N=1,617, patients with ASCVD or ASCVD risk equivalents including HeFH) showed a 49.9% reduction versus a 0.8% increase in placebo (P<0.001) [19].

Pooled analysis from ORION-9, -10, and -11 (combined N approximately 3,600 patients) confirmed a mean LDL-C reduction of approximately 50% that was sustained over the full trial period with a twice-yearly dosing schedule [20]. The most common adverse event was injection-site reactions, occurring in 4.7% of inclisiran patients versus 0.8% of placebo patients, generally mild and self-limiting [19].

The 2022 ACC Expert Consensus noted that "inclisiran's unique mechanism of action and infrequent dosing schedule may improve adherence compared with daily oral medications or monthly subcutaneous injections" [6]. Long-term cardiovascular outcomes data from the ORION-4 trial (NCT03705234), which is currently enrolling approximately 15,000 patients with prior MI or stroke, are expected to report around 2026 and will be critical for formulary decisions [21].

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states that for very high-risk ASCVD patients with LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy, a PCSK9 inhibitor is reasonable (Class IIa, Level of Evidence A) [22]. Inclisiran falls within that PCSK9 category for clinical decision-making, even though the specific guideline language predates FDA approval of inclisiran.

Can I Get Leqvio Prescribed via Telehealth in Kentucky?

Yes. Kentucky law permits telehealth prescribing of Leqvio. Kentucky Revised Statute 311.597 and the Kentucky Board of Medical Licensure's telehealth regulations allow physicians to prescribe medications following a telehealth evaluation, provided the prescribing standards applicable to in-person visits are met [23].

Because Leqvio is administered by injection in a clinical setting rather than self-administered, a telehealth visit can initiate the prescription and coordinate care with a local infusion center, cardiology office, or primary care clinic that will perform the injection. This two-step model, telehealth consult plus local administration, is fully compatible with Kentucky law and with Leqvio's prescribing requirements [24].

HealthRX providers licensed in Kentucky can evaluate patients for Leqvio candidacy via a telehealth visit, review lipid panels and prior authorization requirements, and coordinate injection administration with a local provider. Patients need a recent lipid panel (within 90 days is typically adequate) and documentation of maximally tolerated statin therapy before an evaluation.

What Is the Cheapest Way to Get Leqvio in Kentucky?

The answer depends on insurance status.

Commercially insured patients. Apply for the Novartis copay card immediately after a prescription is written. Many eligible patients end up paying $0 per injection. The prior authorization process adds time; work with the prescriber's office to submit documentation of statin history and current LDL simultaneously with the prescription [13].

Uninsured patients with income at or below 400% FPL. Apply for the Novartis PAP. If income exceeds PAP thresholds but the cash price is prohibitive, a licensed 503A compounding pharmacy in Kentucky is a legal alternative worth discussing with your prescriber [14].

Medicare patients. Under the IRA's $2,000 annual cap, most Part D enrollees reaching the catastrophic coverage phase will have limited additional out-of-pocket exposure. Confirm whether the plan covers inclisiran under Part B (physician-administered) or Part D (pharmacy-dispensed), as the Part B pathway sometimes results in lower cost-sharing [11].

Medicare and Medicaid patients ineligible for the copay card. Request that the prescribing provider document clinical necessity for a prior authorization appeal. If denied, compounded inclisiran from a licensed 503A Kentucky pharmacy is a legal option that some patients pursue after discussing risks with their provider [15].

A 2023 analysis in Circulation: Cardiovascular Quality and Outcomes found that patients who received cardiovascular risk-reduction medications through telehealth-initiated programs had 18% higher 12-month persistence rates compared with patients who received prescriptions through traditional outpatient cardiology visits alone [25]. Better adherence translates directly to better LDL control over time.

Monitoring LDL-C After Starting Inclisiran in Kentucky

After the first injection, a fasting lipid panel at Day 90 (the time of the second loading dose) is standard practice to confirm therapeutic response. A reduction of 40 to 55% from baseline LDL-C is the expected range based on ORION trial data [19]. Patients who show less than 30% reduction should prompt a review of medication authenticity, injection technique, and concurrent dietary changes [20].

Subsequent monitoring at 6 months (aligned with the maintenance injection schedule) is sufficient for stable patients. The ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after initiating or changing lipid therapy [22]. Many Kentucky cardiologists and primary care physicians order the panel at the same visit as the injection to simplify logistics.

Hepatic function testing is not routinely required for inclisiran, unlike some other lipid agents. The ORION-10 and ORION-11 trials showed no significant difference in liver enzyme elevations between inclisiran and placebo groups [19].

Prior Authorization Tips for Kentucky Prescribers

Prior authorization for Leqvio in Kentucky typically requires:

1. Documentation of a diagnosis of HeFH (confirmed by genetic testing or Dutch Lipid Clinic Network score, or clinical diagnosis) or established ASCVD (prior MI, stroke, or peripheral arterial disease).
2. Current LDL-C level on maximally tolerated statin therapy, generally above 70 mg/dL for ASCVD patients.
3. Documentation of a trial of maximally tolerated statin (usually high-intensity atorvastatin or rosuvastatin for at least 8 to 12 weeks).
4. Evidence of ezetimibe trial or documented intolerance.
5. In some plans, documentation of an inadequate response to or intolerance of a PCSK9 monoclonal antibody (alirocumab or evolocumab) [10].

The 2022 ACC Expert Consensus Decision Pathway provides structured criteria that map closely to commercial payer requirements and can be cited directly in prior authorization letters [6]. Novartis also maintains a hub services program called the Leqvio 360 Support program, accessible through the prescriber portal, that can assist Kentucky practices with PA submission and patient enrollment in cost assistance programs [13].

Kentucky-Specific Resources for Leqvio Access

The Kentucky Department for Public Health's Heart Disease and Stroke Prevention Program coordinates with federally qualified health centers (FQHCs) across the state to improve cardiovascular risk factor management [26]. FQHCs operating under Section 340B of the Public Health Service Act can purchase outpatient drugs at significantly discounted 340B prices. Leqvio is a 340B-eligible drug, meaning qualifying Kentucky FQHCs and rural health clinics may be able to offer it to uninsured or underinsured patients at substantially reduced cost. Patients should ask whether their community health center is a 340B-covered entity.

The University of Kentucky Gill Heart and Vascular Institute and the University of Louisville Heart and Vascular Institute both operate lipid disorder clinics that manage patients with HeFH and refractory hypercholesterolemia. Both centers have institutional experience navigating PCSK9 prior authorizations and may have access to manufacturer patient support programs that smaller practices lack [27].